SANUWAVE Health Crushes Q3 Revenue Expectations; Sales Increase 895% As UltraMIST(R) Adds Accretive Punch To Already Strong Wound-Care Device Pipeline

About this update from Sanuwave Health, Inc.

[{"type":"text","content":"Miami Beach, Florida--(Newsfile Corp. - December 3, 2020) - SANUWAVE Health (OTCQB: SNWV) published a blowout quarter in November that showed revenue increasing by roughly 895% to $1,966,896 compared to the same period in 2019. The report was bullish from a value-trade perspective. But it also detailed how the company is exceptionally well-positioned to add immediate and accretive revenue streams from its acquisition of UltraMIST® along with two important biologics, BIOVANCE® and Interfyl®, licensed from Celularity in the same deal.\n\nThe report left little doubt that the quarter was robust on the revenue side- they posted record levels. But, as good as that achievement is, investors are evaluating several new tangibles that can position the company to achieve even greater success in the coming weeks and months. First, a developing revenue stream from its biologics assets, especially BIOVANCE, should not go unnoticed. Second, the combination-therapy potential from its DermaPACE and UltraMIST diabetic wound-care devices can be best-in-class alternatives to current and painful treatments. That, of course, opens the door to substantial front-line opportunities. And, third, an uplist of the stock to a more senior exchange is imminent. The combination of the three made the third-quarter transformational. It may set-up the fourth-quarter as the breakout period.\n\nWhat matters most is that SANUWAVE's FDA-cleared combination treatment is effective, which is the most critical part of the equation. As a result, the devices and therapy are earning reimbursement coverage from the largest Medicare/Medicaid Administrators in the country. BIOVANCE, too, is achieving its share of reimbursement inclusions, which adds an additional revenue source to the already record-setting numbers.\n\nRevenue can grow for additional reasons.\n\n\nCannot view this video? Visit:\nhttps://www.youtube.com/watch?v=a7NzXi6gFqw\nExpansion Into Latin Markets\n\nNotably, the surge in revenue during the third quarter was driven by sales in the USA. Now, the geographic markets have gotten bigger after SANUWAVE reported receiving regulatory approval from COFEPRIS that they say can leverage opportunity through a Joint Venture on Mexico to market and distribute dermaPACE® to treat chronic wounds. Further, the company received ANVISA approval to market dermaPACE to treat c...

More updates from Sanuwave Health, Inc.